Back

SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation Study

Sato, K.; Ihara, R.; Kurihara, M.; Suzuki, F.; Tokumaru, A.; Niimi, Y.; Iwatsubo, T.

2026-06-24 neurology
10.64898/2026.06.22.26356283 medRxiv
Show abstract

INTRODUCTION: Anti-amyloid therapy eligibility excludes patients with five or more cerebral microhemorrhages (CMHs), but current guidance allows either T2*-GRE or the more sensitive SWI. This may create sequence-dependent differences in eligibility classification. METHODS: We fitted a Bayesian right-censored zero-inflated Poisson model to single-center real-world SWI-based CMH counts from 130 memory clinic patients. We then simulated T2*-GRE counts under a directional binomial detection model across a range of relative detection probabilities and estimated two metrics: P(T2* <5 | SWI [&ge;]5) and P(SWI [&ge;]5 | T2* <5). RESULTS: The model estimated a zero-inflation probability of 0.57 and a Poisson mean of 2.29 in the susceptible subpopulation. In the illustrative 60% relative-detection scenario, the model estimated nearly 80% under-detection among SWI-ineligible patients, whereas approximately 5% of T2*-GRE-eligible patients would have been classified as ineligible by SWI. DISCUSSION: A uniform numeric CMH threshold may not be operationally equivalent across SWI and T2*-GRE. Standardized paired-sequence outcome studies are needed to determine whether SWI-defined and T2*-GRE-defined thresholds carry equivalent ARIA risk.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.